Information Provided By:
Fly News Breaks for February 13, 2020
INCY
Feb 13, 2020 | 11:26 EDT
Piper Sandler analyst Tyler Van Buren maintained an Overweight rating and $95 price target on Incyte (INCY) following the company's "good" Q4 earnings report, where the company reported better than expected revenues that drove cash earnings 61% higher year-over-year. Going forward, the analyst believes Jakafi, which the company guided 2020 sales modestly above the firm's expectations, is "underappreciated." He also believes the company's pemigatinib and capmatinib launch opportunities later this year are underappreciated.
News For INCY From the Last 2 Days
INCY
INCY
INCY
INCY
INCY
INCY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.